Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.
Androgen deprivation therapy (ADT) has traditionally formed the mainstay of treatment for advanced/metastatic prostate cancer (PCa); however, it is now also having an increasingly important role in earlier stages of disease. Indeed, in patients with locally advanced or high-risk localised disease, the addition of neoadjuvant and adjuvant hormone therapy is now considered the standard of care for those men treated with radical radiotherapy. Although luteinising hormone-releasing hormone (LHRH) agonists have been used for many years as ADT, they may be associated with clinical flare and testosterone breakthrough. Newer hormonal agents continue to be developed, such as gonadotropin-releasing hormone antagonists, which reduce testosterone and prostate-specific antigen levels more rapidly than LHRH agonists, without testosterone flare. This review examines ADT use in combination with radiotherapy to improve outcomes in localised or locally advanced disease, and examines some of the latest developments in hormonal therapy for PCa.
Department of Clinical Oncology, University College Hospital, 235 Euston Road, London, UK. heather_payne@blueyonder.co.uk
H
H
Payne
M
M
Mason
D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000532:radiotherapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal